SEATTLE, Sept. 8, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at US$ 17,510.15 million in 2022 and is expected to exhibit a CAGR of 4.9% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market:
Increasing approval of generic drugs by regulatory bodies to treat chronic obstructive pulmonary disease is expected to drive the market growth over the forecast period. For instance, in March 2022, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions, asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2656
Key Market Takeaways:
Global chronic obstructive pulmonary disease (COPD) treatment market is expected to exhibit a CAGR of 4.9% during the forecast period due to increasing adoption of inorganic strategies such as agreements by key players in market. For instance, in May 2022, RS BioTherapeutics, company that do research, development, and commercialization of interventions for chronic and acute pulmonary diseases signed a license agreement with Synthonics Inc., a pharmaceutical company for the exclusive, worldwide right to use Synthonics' metal coordinated cannabinoid in nebulized form for the treatment of pulmonary inflammatory disorders. RS BioTherapeutics is developing its lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease.
Among distribution channel, the hospital pharmacies segment is expected to dominate the segment growth over the forecast period, owing to the increased prevalence of the chronic obstructive pulmonary disease and increasing surgeries for chronic obstructive pulmonary disease. For instance, according to the data published by the Center For Disease Control And Prevention, the global prevalence of chronic obstructive pulmonary disease was 10·3% in 2019, accounting for 391·9 million cases among people aged 30-79 years. Age-adjusted death rates for COPD were significantly lower in 2019 compared with 1999 among U.S. men (57.0 per 100,000 in 1999 and 40.5 per 100,000 in 2019) and among U.S. women (35.3 per 100,000 in 1999 and 34.3 per 100,000 in 2019).
Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2656
Detailed Segmentation:
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
- Bronchodilators
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Others
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
- Oral
- Inhalation
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Europe
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- By Country:
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/2656
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner - Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
LOGO: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
